DOP2009000295A - Compuestos de bencensulfonamida apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3 - Google Patents

Compuestos de bencensulfonamida apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3

Info

Publication number
DOP2009000295A
DOP2009000295A DO2009000295A DO2009000295A DOP2009000295A DO P2009000295 A DOP2009000295 A DO P2009000295A DO 2009000295 A DO2009000295 A DO 2009000295A DO 2009000295 A DO2009000295 A DO 2009000295A DO P2009000295 A DOP2009000295 A DO P2009000295A
Authority
DO
Dominican Republic
Prior art keywords
dopamine
compounds
alkyl
fluorinated
bencensulfonamide
Prior art date
Application number
DO2009000295A
Other languages
English (en)
Inventor
Liliane Unger
Sean Colm Turner
Andreas Haupt
Wilfried Braje
Udo Lange
Karla Drescher
Ana Lucia Jorgen-Relo
Anton Bespalov
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of DOP2009000295A publication Critical patent/DOP2009000295A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Compuestos de formula I R1 se selecciona del grupo que consiste en hidrogeno, Cl-C3 alquilo lineal y C1-C3 alquilo lineal fluorado; R2 es hidrogeno o metilo; R3 se selecciona del grupo que consiste en hidrogeno, halogeno, C -C2-alquilo, C1-C2-alquilo fluorado, C1-C2-alcoxilo Y Cl-C2-alcoxilo fluorado, R4 es C1-C2-alquilo o C1-C2-alquilo fluorado; n es 0, 1 o 2, y las sales fisiologicamente tolerables de estos compuestos y los N-oxidos de estos. La invencion tambien se relaciona con una composicion farmaceutica que comprende al menos un compuesto de formula I y/o al menos una sal de adicion acida fisiologicamente tolerable de este, y ademas, con un metodo para tratar trastornos que responden beneficiosamente a los antagonistas del receptor de dopamina D3 o los agonistas de dopamina D3, donde dicho metodo comprende administrarle una cantidad eficaz de al menos un compuesto o una sal de adicion acida fisiologicamente tolerable de formula I a un sujeto que lo necesita.
DO2009000295A 2007-10-31 2009-12-29 Compuestos de bencensulfonamida apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3 DOP2009000295A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07119788 2007-10-31

Publications (1)

Publication Number Publication Date
DOP2009000295A true DOP2009000295A (es) 2010-01-31

Family

ID=40280677

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2009000295A DOP2009000295A (es) 2007-10-31 2009-12-29 Compuestos de bencensulfonamida apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3

Country Status (24)

Country Link
US (4) US20100210664A1 (es)
EP (1) EP2203426B9 (es)
JP (1) JP5680416B2 (es)
KR (1) KR20100080500A (es)
CN (1) CN101687802B (es)
AT (1) ATE522505T1 (es)
AU (1) AU2008320875B2 (es)
BR (1) BRPI0812978A2 (es)
CA (1) CA2690976A1 (es)
CO (1) CO6251289A2 (es)
CR (1) CR11188A (es)
DO (1) DOP2009000295A (es)
EC (1) ECSP099832A (es)
ES (1) ES2371308T3 (es)
GT (1) GT200900332A (es)
IL (1) IL202814A (es)
MX (1) MX2009014236A (es)
MY (1) MY153300A (es)
NZ (1) NZ582095A (es)
RU (1) RU2485103C2 (es)
TW (1) TWI469782B (es)
UA (1) UA99628C2 (es)
WO (1) WO2009056600A1 (es)
ZA (1) ZA200909171B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201509186TA (en) 2013-06-27 2016-01-28 Pfizer Heteroaromatic compounds and their use as dopamine d1 ligands
JP7584757B2 (ja) * 2021-05-18 2024-11-18 テックウインド株式会社 顔画像データから燃え尽き症候群を検知し離職を予測するシステム

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102439D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
US7320979B2 (en) * 2003-04-14 2008-01-22 Abbott Gmbh & Co. Kg. N-[(piperazinyl)hetaryl]arylsulfonamide compounds
US20040204422A1 (en) * 2003-04-14 2004-10-14 Abbott Gmbh & Co. Kg. N-[(Piperazinyl)hetaryl]arylsulfonamide compounds

Also Published As

Publication number Publication date
IL202814A0 (en) 2010-06-30
TWI469782B (zh) 2015-01-21
AU2008320875B2 (en) 2013-08-01
WO2009056600A1 (en) 2009-05-07
ECSP099832A (es) 2010-01-29
ATE522505T1 (de) 2011-09-15
TW200932234A (en) 2009-08-01
UA99628C2 (ru) 2012-09-10
MX2009014236A (es) 2010-05-03
ZA200909171B (en) 2012-05-30
CA2690976A1 (en) 2009-05-07
RU2485103C2 (ru) 2013-06-20
US20110319421A1 (en) 2011-12-29
ES2371308T3 (es) 2011-12-29
US20150175570A1 (en) 2015-06-25
AU2008320875A1 (en) 2009-05-07
CO6251289A2 (es) 2011-02-21
RU2010121830A (ru) 2011-12-10
NZ582095A (en) 2012-08-31
CN101687802A (zh) 2010-03-31
EP2203426A1 (en) 2010-07-07
GT200900332A (es) 2012-04-03
EP2203426B1 (en) 2011-08-31
JP5680416B2 (ja) 2015-03-04
CN101687802B (zh) 2014-02-26
MY153300A (en) 2015-01-29
US20140200224A1 (en) 2014-07-17
CR11188A (es) 2010-05-27
US20100210664A1 (en) 2010-08-19
IL202814A (en) 2015-05-31
JP2011500771A (ja) 2011-01-06
BRPI0812978A2 (pt) 2014-12-16
KR20100080500A (ko) 2010-07-08
EP2203426B9 (en) 2013-02-13

Similar Documents

Publication Publication Date Title
MX2018000179A (es) Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida.
AR072224A1 (es) Derivados de pirimidona sustituidos
PE20142294A1 (es) Compuestos de indol e indazol que activan la ampk
EA200900606A1 (ru) Новые сульфониламидные производные в качестве антагонистов брадикининовых рецепторов
CO6311070A2 (es) Compuestos triazina como inhibidores mtor y quinasa pi3
UY31084A1 (es) Compuestos de azaindol para la inhibicion de b-secretasa
AR072962A1 (es) Derivados de pirimidin-4-ona sustituidos
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
EA200900605A1 (ru) Новые производные фенилсульфамоил бензамидов в качестве антагонистов брадикининовых рецепторов
BRPI0716069A2 (pt) composto, composiÇço farmacÊutica, e, mÉtodo para tratar um distérbio
PE20091450A1 (es) INHIBIDORES DE LA ESTEAROIL-CoA-DESATURASA
AR070485A1 (es) Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
PE20080364A1 (es) Acido bifenilcarboxilicos substituidos y sus derivados como moduladores de la actividad de la gamma-secretasa
EA200901474A1 (ru) Соли [4-(6-фтор-7-метиламино-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины в различных кристаллических формах и фармацевтические композиции на их основе
ECSP066536A (es) Derivados de acidos fenoxiaceticos utiles como agonistas dobles dereceptor activado por proliferador de peroxisoma
ECSP088257A (es) Derivados de amida
PE20080949A1 (es) Azolilmetiloxiranos, su uso para combatir hongos fitopatogenos, asi como productos que los contienen
CL2009001146A1 (es) Compuestos derivados de 5-(5-(2-(3,5-bis(trifluorometil)fenil)-n,2-dimetilpropanoamida)-4-(4-fluoro-2-metilfenil)piridin-2-il)pirrolidin-2-carboxamida, antagonistas de los receptores nk-1; composicion farmaceutica; y uso del compuesto para el tratamiento de la depresion; ansiedad, trastornos del sueño o emesis.
PE20081495A1 (es) Derivados 4,5-difenilpirrol-2-carboxamida como antagonistas de los receptores cb1
CR11860A (es) Derivados de dibenzotiazepina y sus usos - 424
AR075262A1 (es) Compuestos de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno, proceso para prepararlos, composicion farmaceutica que los comprende, sus usos como medicamentos, o en tratamientos o prevenciones de condiciones asociadas con un funcionamiento alterado de los sistemas regulados por la melatonina, sus usos para
DOP2010000126A (es) Compuestos de 1,2,4-triazin-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de dopamina d3
AR054341A1 (es) Combinaciones sinergicas de compuestos activos fungicidas
DOP2009000295A (es) Compuestos de bencensulfonamida apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3